Cerebrospinal fluid (CSF) samples are increasingly being used for genomic profiling of brain tumors, offering a less invasive alternative to tissue biopsies. CSF samples provide a higher signal-to-noise ratio for detecting tumor-derived cell-free DNA (cfDNA) compared to plasma samples, making them particularly useful for …
The upcoming ASCO 2026 meeting will focus on the clinical application of AI in cancer care, emphasizing multimodal AI models that integrate pathology, radiology, molecular data, and liquid biopsy.
SPONSORED ROUNDTABLES
Thermo Fisher Scientific’s SwiftArrayStudio microarray analyzer was developed in response to customer needs for simpler workflows, more consistent turnaround times, and lower operational burden in genomics labs.
CAP TODAY RECOMMENDS
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Billing
Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
January 2014—Transgenomic in October announced the results of a research collaboration with MD Anderson Cancer Center employing the company’s ICE COLD-PCR platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free DNA present in the blood as were originally found in primary tumors. In a subset of patients followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.